COLTENE (CLTN) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
24 Jul, 2026Executive summary
Net sales declined 7.4% year-over-year to CHF 118.1 million in H1 2025, mainly due to geopolitical uncertainty, currency headwinds, and temporary order delays from dealer management changes.
EBIT margin dropped to 6.4% from 10.2% in the prior year, reflecting lower sales, market volatility, and operational challenges.
Net profit fell 59.1% to CHF 4.3 million, mainly due to lower EBIT and higher FX losses.
Strategic focus remains on efficiency, customer orientation, and innovation, with new product launches and digitisation initiatives underway.
Leadership changes include a new Chairman and Board member, with the former CEO joining the Board.
Financial highlights
Gross profit margin slightly decreased by 0.2pp to 66.4%.
Free cash flow was weak at CHF -0.3 million, compared to CHF 13.8 million last year, mainly due to higher inventories.
Net debt increased significantly to CHF 34.6 million from CHF 18.1 million at year-end 2024.
Equity ratio decreased to 51.0% from 58.2% at year-end 2024.
EBITDA margin dropped to 9.2% from 12.9% in H1 2024.
Outlook and guidance
Short-term outlook remains highly volatile due to geopolitical uncertainty and US tariffs.
2025 EBIT margin expected around 10% (previously 11%).
Medium-term (2027) targets: annual sales growth of 3-5% in local currencies, EBIT margin of 13-15%, and payout ratio of about 70%, assuming geopolitical stability.
No revenue guidance provided due to limited market visibility.
Results are expected to improve significantly in the second half as order delays normalize and new products launch.
Latest events from COLTENE
- Net sales down 4.4%, EBIT margin at 5.1%, free cash flow up, outlook for modest growth.CLTN
H1 202631 Jul 2026 - Net profit rose 3.9% despite lower sales, with strong margins and a positive outlook.CLTN
H1 202424 Jul 2026 - Net profit rose to CHF 20.5m as sales and margins improved, led by North America.CLTN
H2 202424 Jul 2026 - Net profit fell 27% and EBIT margin dropped to 8.8%, with growth and margin recovery targeted for 2026.CLTN
H2 202513 Mar 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026